Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model. The Dow Jones Industrial Average ( ^DJI) is trading up 69 points (+0.5%) at 14,745 as of Thursday, Apr 25, 2013, 11:35 a.m. ET. During this time, 268.4 million shares of the 30 Dow components have changed hands vs. an average daily trading volume of 600.4 million. The NYSE advances/declines ratio sits at 2,132 issues advancing vs. 754 declining with 119 unchanged.
EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
Holding back the Dow today is Procter & Gamble (NYSE: PG), which is lagging the broader Dow index with a 14-cent decline (-0.2%) bringing the stock to $76.98. Volume for Procter & Gamble currently sits at 5.6 million shares traded vs. an average daily trading volume of 9.4 million shares. Procter & Gamble has a market cap of $225.47 billion and is part of the consumer goods sector and consumer non-durables industry. Shares are up 13.6% year to date as of Wednesday's close. The stock's dividend yield sits at 2.9%. The Procter & Gamble Company, together with its subsidiaries, engages in the manufacture and sale of a range of branded consumer packaged goods. The company operates in five segments: Beauty, Grooming, Health Care, Fabric Care and Home Care, and Baby Care and Family Care. The company has a P/E ratio of 21.2, above the S&P 500 P/E ratio of 17.7. TheStreet Ratings rates Procter & Gamble as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, expanding profit margins, good cash flow from operations and compelling growth in net income. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.